Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

2.

Varicella Vaccine: What Have You Done for Me Lately?

Gershon AA.

Pediatrics. 2019 Jul;144(1). pii: e20183561. doi: 10.1542/peds.2018-3561. Epub 2019 Jun 10. No abstract available.

PMID:
31182550
3.

The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.

Sauboin C, Holl K, Bonanni P, Gershon AA, Benninghoff B, Carryn S, Burgess MA, Wutzler P.

BMC Infect Dis. 2019 Feb 6;19(1):126. doi: 10.1186/s12879-019-3759-z.

4.

Ropinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study.

Gershon AA, Amiaz R, Shem-David H, Grunhaus L.

J Clin Psychopharmacol. 2019 Jan/Feb;39(1):78-81. doi: 10.1097/JCP.0000000000000984.

PMID:
30489382
5.

High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine.

Gershon AA, Brooks D, Stevenson DD, Chin WK, Oldstone MBA, Gershon MD.

J Infect Dis. 2019 Apr 8;219(8):1338-1346. doi: 10.1093/infdis/jiy660.

PMID:
30445431
6.

Clinical Features of Varicella-Zoster Virus Infection.

Kennedy PGE, Gershon AA.

Viruses. 2018 Nov 2;10(11). pii: E609. doi: 10.3390/v10110609. Review.

7.

Tale of two vaccines: differences in response to herpes zoster vaccines.

Gershon AA.

J Clin Invest. 2018 Oct 1;128(10):4245-4247. doi: 10.1172/JCI123217. Epub 2018 Sep 4.

8.

Shingles vaccine after auto-HSCT decreases risk.

Macartney K, Gershon AA.

Lancet. 2018 May 26;391(10135):2082-2084. doi: 10.1016/S0140-6736(18)30909-7. Epub 2018 May 24. No abstract available.

PMID:
29856333
9.

Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA.

Vaccine. 2017 Dec 19;35(52):7231-7239. doi: 10.1016/j.vaccine.2017.11.013. Epub 2017 Nov 22. Review.

10.

Varicella Virus Vaccination in the United States.

Shaw J, Gershon AA.

Viral Immunol. 2018 Mar;31(2):96-103. doi: 10.1089/vim.2017.0136. Epub 2017 Nov 27. Review.

11.

Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Gershon AA.

J Infect. 2017 Jun;74 Suppl 1:S27-S33. doi: 10.1016/S0163-4453(17)30188-3. Review.

12.

THE JEREMIAH METZGER LECTURE VARICELLA ZOSTER VIRUS: FROM OUTSIDE TO INSIDE.

Gershon AA, Gershon MD.

Trans Am Clin Climatol Assoc. 2016;127:282-299.

13.

Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms.

Depledge DP, Yamanishi K, Gomi Y, Gershon AA, Breuer J.

J Virol. 2016 Sep 12;90(19):8698-704. doi: 10.1128/JVI.00998-16. Print 2016 Oct 1.

14.

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, Fulkerson J, Zak DE, Walker R, McClain B, Sadoff J, Scott J, Shepherd B, Ishmukhamedov J, Hokey DA, Dheenadhayalan V, Shankar S, Amon L, Navarro G, Podyminogin R, Aderem A, Barker L, Brennan M, Wallis RS, Gershon AA, Gershon MD, Steinberg S.

EBioMedicine. 2016 May;7:278-86. doi: 10.1016/j.ebiom.2016.04.010. Epub 2016 Apr 19.

15.

Varicella Zoster Virus and Giant Cell Arteritis.

Gershon AA, Gershon M.

J Infect Dis. 2016 Jun 15;213(12):1859-61. doi: 10.1093/infdis/jiw110. Epub 2016 Mar 31. No abstract available.

16.

Applying Transcranial Magnetic Stimulation (TMS) Over the Dorsal Visual Pathway Induces Schizophrenia-like Disruption of Perceptual Closure.

Amiaz R, Vainiger D, Gershon AA, Weiser M, Lavidor M, Javitt DC.

Brain Topogr. 2016 Jul;29(4):552-60. doi: 10.1007/s10548-016-0487-1. Epub 2016 Mar 28.

PMID:
27021230
18.

Neonatal Herpes Infection Associated With Direct Orogenital Suction During Ritual Jewish Circumcision.

Pellett Madan R, Herold BC, Ratner AJ, Saiman L, Gershon AA, Stanberry LR.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):283-4. doi: 10.1093/jpids/piv021. Epub 2015 Apr 24. No abstract available.

19.

Use of Saliva to Identify Varicella Zoster Virus Infection of the Gut.

Gershon AA, Chen J, Gershon MD.

Clin Infect Dis. 2015 Aug 15;61(4):536-44. doi: 10.1093/cid/civ320. Epub 2015 Apr 16.

20.

Rates of vaccine evolution show strong effects of latency: implications for varicella zoster virus epidemiology.

Weinert LA, Depledge DP, Kundu S, Gershon AA, Nichols RA, Balloux F, Welch JJ, Breuer J.

Mol Biol Evol. 2015 Apr;32(4):1020-8. doi: 10.1093/molbev/msu406. Epub 2015 Jan 6.

21.

Varicella zoster virus infection.

Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, Seward JF, Yamanishi K.

Nat Rev Dis Primers. 2015 Jul 2;1:15016. doi: 10.1038/nrdp.2015.16. Review.

22.

Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation.

Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P, Steinberg S, Gershon AA.

Clin Infect Dis. 2015 Apr 1;60(7):1068-74. doi: 10.1093/cid/ciu970. Epub 2014 Dec 1. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

23.

Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay.

Cohen JI, Ali MA, Bayat A, Steinberg SP, Park H, Gershon AA, Burbelo PD.

Clin Vaccine Immunol. 2014 Sep;21(9):1288-91. doi: 10.1128/CVI.00250-14. Epub 2014 Jul 2.

24.

Infected peripheral blood mononuclear cells transmit latent varicella zoster virus infection to the guinea pig enteric nervous system.

Gan L, Wang M, Chen JJ, Gershon MD, Gershon AA.

J Neurovirol. 2014 Oct;20(5):442-56. doi: 10.1007/s13365-014-0259-1. Epub 2014 Jun 26.

25.

Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder.

Weiser M, Burshtein S, Gershon AA, Marian G, Vlad N, Grecu IG, Tocari E, Tiugan A, Hotineanu M, Davis JM.

Bipolar Disord. 2014 Jun;16(4):441-7. doi: 10.1111/bdi.12202. Epub 2014 Apr 8.

PMID:
24712840
26.

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Gershon AA, Gershon MD.

Clin Microbiol Rev. 2013 Oct;26(4):728-43. doi: 10.1128/CMR.00052-13. Review.

27.

Strokes and infection with varicella zoster virus.

Gershon AA.

Clin Infect Dis. 2014 Jan;58(1):69-71. doi: 10.1093/cid/cit663. Epub 2013 Oct 2. No abstract available.

PMID:
24092800
28.

Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children.

Gershon AA, Chen J, Davis L, Krinsky C, Cowles R, Reichard R, Gershon M.

Trans Am Clin Climatol Assoc. 2012;123:17-33; discussion 33-5.

29.

Varicella zoster vaccines and their implications for development of HSV vaccines.

Gershon AA.

Virology. 2013 Jan 5;435(1):29-36. doi: 10.1016/j.virol.2012.10.006. Review.

30.

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.

J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.

PMID:
22795211
31.

A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.

Weiser M, Gershon AA, Rubinstein K, Petcu C, Ladea M, Sima D, Podea D, Keefe RS, Davis JM.

Schizophr Res. 2012 Jun;138(1):35-8. doi: 10.1016/j.schres.2012.02.014. Epub 2012 Apr 4.

PMID:
22483162
32.

Varicella zoster virus (VZV) infects and establishes latency in enteric neurons.

Chen JJ, Gershon AA, Li Z, Cowles RA, Gershon MD.

J Neurovirol. 2011 Dec;17(6):578-89. doi: 10.1007/s13365-011-0070-1. Epub 2011 Dec 22.

33.

Neonatal herpes simplex infection and the Three Musketeers.

Gershon AA.

N Engl J Med. 2011 Oct 6;365(14):1338-9. doi: 10.1056/NEJMe1107953. No abstract available.

34.

The history and mystery of VZV in saliva.

Gershon AA.

J Infect Dis. 2011 Sep 15;204(6):815-6. doi: 10.1093/infdis/jir417. No abstract available.

35.

Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

Lafer MM, Weckx LY, de Moraes-Pinto MI, Garretson A, Steinberg SP, Gershon AA, LaRussa PS.

Clin Vaccine Immunol. 2011 Jul;18(7):1194-7. doi: 10.1128/CVI.05130-11. Epub 2011 May 25.

36.

Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection.

Oxman MN, Gershon AA, Poland GA.

Vaccine. 2011 May 9;29(20):3625-7. doi: 10.1016/j.vaccine.2011.04.019. No abstract available.

37.

Population diversity in batches of the varicella Oka vaccine.

Kanda RK, Quinlivan ML, Gershon AA, Nichols RA, Breuer J.

Vaccine. 2011 Apr 12;29(17):3293-8. doi: 10.1016/j.vaccine.2011.02.021. Epub 2011 Feb 22.

38.

Varicella-zoster vaccine.

Gershon AA.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 70.

39.

Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient.

Bernstein P, Furuya Y, Steinberg S, Scully B, Larussa P, Gershon AA.

Am J Infect Control. 2011 Apr;39(3):247-9. doi: 10.1016/j.ajic.2010.06.027. Epub 2011 Jan 26.

40.

Effectiveness of 2 doses of varicella vaccine in children.

Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, LaRussa PS, Gershon AA.

J Infect Dis. 2011 Feb 1;203(3):312-5. doi: 10.1093/infdis/jiq052.

41.

Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers.

McDonald SL, Maple PA, Andrews N, Brown KE, Ayres KL, Scott FT, Al Bassam M, Gershon AA, Steinberg SP, Breuer J.

J Virol Methods. 2011 Mar;172(1-2):60-5. doi: 10.1016/j.jviromet.2010.12.021. Epub 2010 Dec 28.

42.

Transmission of varicella vaccine virus to a non-family member in China.

Gan L, Wang M, Yang S, Gershon AA, Chen JJ.

Vaccine. 2011 Mar 3;29(11):2015-7. doi: 10.1016/j.vaccine.2010.11.071. Epub 2010 Dec 4.

43.

Effect of varicella-zoster virus (VZV) fluorescent-antibody-to-membrane-antigen (FAMA) testing on sensitivity of determining VZV immunity in healthcare workers and on furlough days.

Rolando L, Schneider WJ, Steinberg S, Low S, Stiles J, Gomez L, Gershon AA, Brown AE.

Infect Control Hosp Epidemiol. 2010 Sep;31(9):972-4. doi: 10.1086/655840. No abstract available.

44.

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.

Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD.

J Clin Virol. 2010 May;48 Suppl 1:S2-7. doi: 10.1016/S1386-6532(10)70002-0. Review.

45.

Prevention strategies for herpes zoster and post-herpetic neuralgia.

Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L.

J Clin Virol. 2010 May;48 Suppl 1:S14-9. doi: 10.1016/S1386-6532(10)70004-4. Review.

46.

Effectiveness of varicella vaccine in children infected with HIV.

Son M, Shapiro ED, LaRussa P, Neu N, Michalik DE, Meglin M, Jurgrau A, Bitar W, Vasquez M, Flynn P, Gershon AA.

J Infect Dis. 2010 Jun 15;201(12):1806-10. doi: 10.1086/652798.

47.

Perspectives on vaccines against varicella-zoster virus infections.

Gershon AA, Gershon MD.

Curr Top Microbiol Immunol. 2010;342:359-72. doi: 10.1007/82_2010_12.

48.

VZV infection of keratinocytes: production of cell-free infectious virions in vivo.

Gershon MD, Gershon AA.

Curr Top Microbiol Immunol. 2010;342:173-88. doi: 10.1007/82_2010_13. Review.

49.

Vaccination against varicella: what's the point?

Gershon AA.

Adv Exp Med Biol. 2010;659:83-7. doi: 10.1007/978-1-4419-0981-7_7. Review. No abstract available.

50.

Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, Silber JL, MacGregor RR, Chan K, Gershon AA, Levin MJ.

J Infect Dis. 2010 Apr 1;201(7):1024-30. doi: 10.1086/651199.

Supplemental Content

Loading ...
Support Center